Arno Therapeutics Inc (ARNI)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Arno Therapeutics Inc (ARNI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013223
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arno Therapeutics Inc (Arno) is a clinical stage biopharmaceutical company that develops products for the treatment of cancer, infectious diseases and other life threatening diseases. The company has exclusive worldwide rights for the development and commercialization of Onapristone (for the treatment of breast and endometrial cancer) with Invivis Pharmaceuticals, Inc.; AR-42 (for hematological malignancies and solid tumors); and AR-12, (for solid tumors and lymphoma) with the Ohio State University. These compounds are in clinical or preclinical stages of development. The company has agreements with pharmaceutical companies and research institutes to develop its product portfolio. Arno Therapeutics is headquartered in Flemington, New Jersey, the US.

Arno Therapeutics Inc (ARNI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Arno Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Arno Therapeutics Enters into R&D Agreement with US Army Medical Research Institute of Infectious Diseases 12
Licensing Agreements 13
Arno Therapeutics Enters Into Licensing Agreement With University of Minnesota 13
Arno Therapeutics Enters into Licensing Agreement with Invivis Pharma for Onapristone 14
Equity Offering 15
Arno Therapeutics to Raise Funds through Public Offering of Shares 15
Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 16
Arno Therapeutics Raises USD5.3 Million in Private Placement of Shares 18
Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 19
Arno Therapeutics Completes Private Placement Of Units For US$30.7 Million 21
Debt Offering 23
Arno Therapeutics Raises USD2 Million in Private Placement of 6% Notes Due 2016 23
Arno Therapeutics Completes Private Placement Of Debentures Due 2015 For Additional US$2 Million 24
Asset Transactions 26
Vivacitas Oncology Acquires Preclinical and Clinical Data Package from Arno Therapeutics 26
Arno Therapeutics Inc – Key Competitors 27
Arno Therapeutics Inc – Key Employees 28
Arno Therapeutics Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Nov 14, 2016: Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update 30
Aug 22, 2016: Arno Therapeutics Reports Second Quarter 2016 Financial and Business Update 31
May 16, 2016: Arno Therapeutics Reports First Quarter 2016 Financial and Business Update 33
Mar 30, 2016: Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update 34
Clinical Trials 35
Apr 19, 2016: Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA 35
Mar 21, 2016: Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Arno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Arno Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Arno Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Arno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Arno Therapeutics Enters into R&D Agreement with US Army Medical Research Institute of Infectious Diseases 12
Arno Therapeutics Enters Into Licensing Agreement With University of Minnesota 13
Arno Therapeutics Enters into Licensing Agreement with Invivis Pharma for Onapristone 14
Arno Therapeutics to Raise Funds through Public Offering of Shares 15
Arno Therapeutics Raises USD2.3 Million in First Tranche of Private Placement of Units 16
Arno Therapeutics Raises USD5.3 Million in Private Placement of Shares 18
Arno Therapeutic Raises USD5.3 Million in Private Placement of Shares 19
Arno Therapeutics Completes Private Placement Of Units For US$30.7 Million 21
Arno Therapeutics Raises USD2 Million in Private Placement of 6% Notes Due 2016 23
Arno Therapeutics Completes Private Placement Of Debentures Due 2015 For Additional US$2 Million 24
Vivacitas Oncology Acquires Preclinical and Clinical Data Package from Arno Therapeutics 26
Arno Therapeutics Inc, Key Competitors 27
Arno Therapeutics Inc, Key Employees 28

★海外企業調査レポート[Arno Therapeutics Inc (ARNI)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • ARCA biopharma Inc (ABIO):医療機器:M&Aディール及び事業提携情報
    Summary ARCA Biopharma Inc (ARCA), formerly Nuvelo Inc is a developer of genetically targeted therapies for cardiovascular diseases. The company’s product candidate include Gencaro, a mild vasodilator and investigational pharmacologically unique beta-blocker that is being developed for the treatment …
  • Aura Light International AB:企業の戦略的SWOT分析
    Aura Light International AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • HSBC Trinkaus & Burkhardt Private Banking:企業の戦略・SWOT・財務情報
    HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report Summary HSBC Trinkaus & Burkhardt Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Factor Therapeutics Ltd (FTT)-医療機器分野:企業M&A・提携分析
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor w …
  • SOSINA Exploration Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Sosina Exploration Ltd (Sosina), formerly Odegaard UK Ltd is an oil and gas company that offers exploration and development services. The company identifies probable oil and gas accumulations in co-operation with partners within the oil and gas industries. It provides services in geological …
  • Pakistan Water and Power Development Authority:電力:M&Aディール及び事業提携情報
    Summary Pakistan Water and Power Development Authority (WAPDA) is a government-owned public authority maintaining power and water in Pakistan. It is responsible for the development of hydel power and water sector projects in Pakistan. The authority plans and executes projects and schemes for the gen …
  • Securities Trust of Scotland plc (STS):企業の財務・戦略的SWOT分析
    Summary Securities Trust of Scotland plc (Securities Trust of Scotland) is a financial service provider that offers capital asset services, broking services, online stock broking services, and online dealing. The company raises income and long term capital growth through investment in a portfolio of …
  • Mochida Pharmaceutical Co Ltd (4534):製薬・医療:M&Aディール及び事業提携情報
    Summary Mochida Pharmaceutical Co Ltd (Mochida) is a pharmaceutical company that develops, manufactures and markets drugs and diagnostic regents. The company's drugs are used for the treatment of arteriosclerosis obliterans, hyperlipidemia, hypertension, angina pectoris, endometriosis, mycosis, thro …
  • Fibrocell Science Inc (FCSC):製薬・医療:M&Aディール及び事業提携情報
    Summary Fibrocell Science Inc (Fibrocell Science) is an autologous cell and gene therapy company which discovers and develops therapies for diseases affecting the skin and connective tissue. The company’s product pipeline comprises FCX-007, a lead candidate for the treatment of recessive dystrophic …
  • Ames Construction Inc:企業の戦略的SWOT分析
    Ames Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Fujifilm Diosynth Biotechnologies USA Inc-製薬・医療分野:企業M&A・提携分析
    Summary Fujifilm Diosynth Biotechnologies USA Inc (Fujifilm Diosynth), a subsidiary of Fujifilm Corp, is a contract development and manufacturing organization that develops therapeutic products, biologics and vaccines. The organization also develops processes for molecules expressed through fermenta …
  • Symphony Ltd:企業の戦略・SWOT・財務情報
    Symphony Ltd - Strategy, SWOT and Corporate Finance Report Summary Symphony Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Airbus Group SE:企業の戦略・SWOT・財務情報
    Airbus Group SE - Strategy, SWOT and Corporate Finance Report Summary Airbus Group SE - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • HeartSciences:医療機器:M&Aディール及び事業提携情報
    Summary HeartSciences, formerly Heart Test Laboratories Inc, is a medical device company that offers cardiac care products. The company develops, manufactures and markets cardiac testing tools for the early detection of heart disease. It offers MyoVista, a screening tool used to determine the presen …
  • Vaisala oyj (VAIAS):企業の財務・戦略的SWOT分析
    Summary Vaisala oyj (Vaisala) is a manufacturer of industrial and environmental measurement products. Its products include automatic weather stations and sensors, aviation weather systems, wireless temperature and humidity data loggers, indoor monitoring systems, weather radar products, rail weather …
  • Arzeda Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Arzeda Corp (Arzeda) is a biotechnology company that develops biological solutions for transformative products. The company’s products include novel crop traits, 1, 3-butadiene, levulinic acid, and methane. Its services comprise enzyme design, metabolic engineering, and protein optimization …
  • Taconic Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • Baxter International Inc.:企業の戦略・SWOT・財務情報
    Baxter International Inc. - Strategy, SWOT and Corporate Finance Report Summary Baxter International Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • GAIL (India) Ltd (GAIL)
    GAIL (India) Ltd (GAIL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • OAO Gazprom:企業の戦略・SWOT・財務情報
    OAO Gazprom - Strategy, SWOT and Corporate Finance Report Summary OAO Gazprom - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆